Randomized data from SWOG 8794 and EORTC 22911 confirm the benefit of post-operative radiation therapy (RT) for selected patients with pT3 prostate cancer (CaP) after radical prostatectomy (RP). However, data regarding the potential benefit of RT for patients post-RP with positive lymph node ( þ LN) involvement are limited. We analyzed the Surveillance Epidemiology End Results (SEER) registry for population-based data on efficacy of postoperative RT for þ LN patients after RP. As LN data have only been captured by SEER since 1988, we analyzed data for 1988-1992, with specific attention to 10-year relative survival (defined as observed survival divided by the survival of a gender-, age-and race-matched population cohort without disease). Specifically analyzed were data for 1921 patients with nonmetastatic prostate cancer who underwent surgery alone, or surgery followed by RT, and who had þ LNs documented. SEER does not code the interval between surgery and RT, so the ratio of patients receiving salvage versus adjuvant therapy is unknown. Using follow-up data through 2002, post-diagnosis survival was examined by number of þ LNs. There was no significant relative survival benefit for þ LN patients receiving post-operative RT (v 2 P ¼ 0.270). These data do not support routine use of postoperative RT for patients with þ LNs in the surgical specimen.
Introduction
Prostate cancer (CaP) in patients with positive lymph nodes ( þ LNs) after radical prostatectomy (RP) and pelvic lymph node sampling (PLNS) represents a difficult clinical dilemma. Although randomized data 1 favor early androgen deprivation (AD) over observation post-operatively in terms of an overall survival benefit for these patients, there are no robust data on the potential benefit of providing post-operative radiation therapy (RT).
The recent publication of EORTC 22911 2 and presentation of SWOG 8794 3 have convincingly shown the benefits of adjuvant RT for selected patients with highrisk CaP post-operatively, and confirm other nonrandomized data on the role of salvage RT, 4 but there were very few patients with þ LN included in those reports. While some data exist for patients receiving definitive RT for patients with þ LNs after PLNS alone, 5-7 these may not be necessarily extrapolated to the post-operative setting, as several surgical series have described reasonable 10-year cause-specific survival (10Y CSS) after RP alone or with AD in these patients ( [8] [9] [10] [11] [12] [13] [14] [15] ; Table 1 ). This is likely due to patient selection based on the extent of LN disease burden and other clinical factors.
Thus, high-quality data are missing to provide for informed decisions as to whether RT post-RP benefits the þ LN patient. We report our investigation using the Surveillance Epidemiology and End Results (SEER) registry.
Materials and methods
The public-access SEER database was queried using the following parameters in the 'Survival' program: Note that this search mechanism provides data for the population of men presenting with nonmetastatic prostate cancer between 1988 and 1992 in the 13 registry SEER database and provides survival specifically for patients with the stated number of þ LNs examined post-operatively. LN data first became available in 1988; 1992 was the last year sampled because follow-up data are complete through 2002, and we desired a 10-year follow-up. Survival data were retrieved for the population of patients undergoing surgery alone, and for those with radiation following surgery. As the SEER database does not code the time interval between surgery and radiation, there is no way of determining whether radiation therapy was delivered in the adjuvant or salvage setting. Similarly, the SEER database does not code particulars of hormonal therapy or of radiation, such as dose, number of fractions or elapsed days in the treatment course.
Owing to the lack of certainty of cause of death in this large registry population, relative survival is used as a surrogate for CSS. Relative survival (RS) is defined within SEER as the observed survival for the cohort as compared to an age-race-and gender-matched sample of the general population. The assumption (likely true for the þ LN CaP population) is that survival differences between the index cohort and the comparison matched cohort is due to effects of disease. Ten year relative survival (10Y RS) was obtained from this search for each of the discrete numbers of þ LNs.
Hormonal therapy is not coded in the public-access SEER registry. The assumption is made that patients receiving AD were equally distributed between RP and RT following RP cohorts.
Results
As expected, patients with þ LNs had worse survival than patients with negative LNs (ÀLNs): when all patients were analyzed, neglecting therapy, observed 10-year survival was 46.7% (standard error (s.e.) þ 1.1%) for þ LN patients and 73.9% (s.e. þ 0.3%) for LNÀ patients. 10Y RS was 72.7% (s.e. þ 1.8%) for þ LN and 100% (s.e. þ 0.5%) for LNÀ. Statistically significant differences for both observed and relative survival were obtained using a w 2 test of contingency tables (Po0.001). Further analysis was made specifically for þ LN patients. Data are available for 1921 patients who underwent surgery alone with at least one þ LN examined: 1409 with surgery alone and 512 who underwent surgery followed by RT. Observed 10-year survival was 46% (s.e. þ 1.3%) for surgery patients and 48.8% (s.e. þ 2.2%) for patients receiving surgery and RT. 10Y RS was 72.3% (s.e. þ 2.1%) and 73.8% (s.e. þ 3.3%), respectively. These survival rates essentially overlap for the RP and RP followed by RT cohorts; statistically nonsignificant w 2 values were obtained for relative survival (P ¼ 0.270). Results by number of þ LNs are displayed in Table 2 . There was no consistent benefit There is a nonsignificant relationship (P ¼ 0.253) between the number of +LNs and RT effect using a T-test on the slope of regression of difference in relative survival as predicted by the number of +LNs.
Post-operative radiation therapy PAS Johnstone et al shown for radiation following surgery, with a nonsignificant relationship between the number of þ LNs and RT effect using a T-test on the slope of regression of difference in relative survival as predicted by the number of þ LNs (P ¼ 0.253). As an example, patients receiving RT had worse 10Y RS if a single LN was positive, but did better than surgery alone if two LNs were involved, and did equally well for three.
Discussion
Although the advent of randomized data for postoperative RT in locally advanced CaP has allowed for a more coherent discussion of RT efficacy under these circumstances, the available data on RT for þ LN CaP post-operatively remain unclear. Results of EORTC trial 22911 2 and SWOG 8794 3 have convincingly shown the benefits of adjuvant RT for selected patients with highrisk CaP post-operatively, and mesh nicely with the retrospective data on the role of salvage RT as presented by Stephenson et al. in 2004 . 4 The data from these trials may not be translated to the þ LN population. Only two patients in the EORTC trial 2 had þ LNs. In the SWOG trial, 3 þ LNs were an exclusionary criteria. Only 14 (3%) of the 501 patients reported by Stephenson et al. 4 had þ LNs. In that analysis, LN status was not predictive of poor outcome, despite the fact that only one þ LN patient had been followed for more than three years without recurrence.
There is a recent resurgence of interest in LNs, as they apply to prognosis and adjuvant therapies in several malignancies, including prostate cancer. This has prompted some authors to move to a more thorough lymph node dissection. Burkhard et al. 16 showed that a meticulous lymph node dissection, including internal iliac chain nodes, resulted in detection of þ LNs in 24% of a 463 patient cohort. When only low-risk patients were examined (PSAo10 and Gleason grade o7), 7% had positive nodes. Schumacher et al., 17 using a updated data set, recently showed that patients with a Gleason grade X7 had a 25% frequency of þ LNs. Data concerning the outcome and utility of adjuvant therapies, such as postprostatectomy RT under these circumstances are thus critical.
Our data show that with a sample of 1921 patients over a 5-year period within the PSA era, there appears to be no consistent survival benefit in those þ LN patients receiving radiation therapy following radical prostatectomy versus those who did not. This finding has important implications for avoiding well-described short-term toxicities from radiation therapy, as well as a low, but measurable incidence of long-term toxicities on urinary function (stricture, hemorrhagic cystitis, etc.) and bowel function. Avoiding adjuvant radiation will result in cost-saving, as well.
To the best of our knowledge, there is only a single small study which has examined the difference in survival between patients with node-positive versus node-negative prostate cancer. Miyake et al. 18 retrospectively analyzed 38 patients with locally advanced prostate cancer receiving post-operative radiation therapy, nine of whom (23%) had positive nodes. There was no statistically significant difference in the 10-year biochemical disease-free survival, however, the number of patients in that study is underpowered to detect a difference in survival, and all of the patients received AD therapy. Besides this small study, prior nonrandomized data are lacking to justify post-operative RT in such patients.
Surgical series (Table 1) have reported extended survival for þ LN patients after RP/PLNS, or after surgery and AD. Although there appears to be significant variability in results between these surgical series, it is certainly not clear that adding further local therapy to the process will make a meaningful difference. Our interpretation of the SEER data is that it does not.
The role of RT in the definitive treatment of CaP patients with known þ LNs has not been addressed in a randomized manner; however, subset analysis of a larger randomized trial (RTOG 85-31) is available for patients receiving RT with hormonal therapy versus RT alone for þ LN CaP. 5 In this review, while there was no significant difference in 9-year absolute survival (50 versus 38%; P ¼ 0.23), progression-free survival (PFS) was significantly better at 9 years for patients receiving hormones (33 versus 4%). Contrary to that, RTOG 9413, 19 that compared whole pelvis RT (WPRT) versus prostate only RT in patients with locally advanced disease and an estimated risk of LN involvement of 415%, showed a 4-year PFS of 54.2% for WPRT versus 47% for prostate only RT (P ¼ 0.022). This benefit was furthered by the addition of neoadjuvant and concurrent AD therapy. This trial concluded that in patients receiving definitive RT for disease with a risk of þ LN 415%, more extensive field RT along with AD therapy is the optimal strategy.
There are limitations to our study, both in terms of necessary assumptions made in the review and in terms of data available in the SEER Registry. First, a fundamental assumption has been made that the patients were being irradiated for prostate cancer, rather than a second malignancy. We consider this to be valid as re-running the SEER search, excluding patients with second primary malignancies, still yielded 1825 cases. Second, we have made the assumption that radiation was delivered for the presence of node-positive disease, rather than a positive surgical margin or a rising PSA (although the reason for irradiation may not matter, as long as it was given). We have also made the assumption that hormonal therapy was equally distributed between the two groups. We believe this assumption is not only necessary, but reasonable, given our observed survival data and the data in Table 1 . In our data, actuarial OS at 10 years was just under 50%. This yields an RS just below 75% in our data, and corresponds with CSS values between 47 and 78% in the literature. Review of the nonrandomized data in Table 1 reveals that early androgen therapy for these patients has been widely practiced for some time in advance of the randomized data reported by Messing and et al. 1 Clearly, data from large registry populations such as CaPSURE or the Center for Prostate Disease Research will enable more precise answers, albeit with lower patient numbers than data from SEER, which contains 26% of the national population data.
In terms of data available within the SEER database, we are unable to quantify the riming of the RT involved and the field sizes and doses used. As SEER data are coded to initial therapy, it is likely that most of these Post-operative radiation therapy PAS Johnstone et al cases received adjuvant therapy, but that point is unverifiable. Finally, no PSA data are available from the SEER registry.
Recognizing these limitations, our review of the SEER database does not show a relative survival advantage for post-operative RT for men who have undergone RP and were found to have þ LN. The decreasing frequency of patients presenting with þ LN after RP renders it unlikely that the role of adjuvant RT could be addressed in a prospective randomized trial, although this may change if clinical practice shifts towards more extensive node dissection techniques.
